---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004189"
form_type: "8-K"
ticker: "SLDB"
cik: "0001707502"
company_name: "Solid Biosciences Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:00:43.087099+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Solid Biosciences appoints Kevin Tan CFO, discloses $214M cash, targets SGT-003 IND in H2 2023

## Summary
- Kevin Tan appointed CFO effective Jan 9, 2023; base salary $425k, 40% bonus target, equity grants.
- Preliminary cash and investments $214M as of Dec 31, 2022 (unaudited).
- Company anticipates submitting IND for SGT-003 in H2 2023 with patient dosing in late 2023.
- Tan previously served as CFO of Selecta Biosciences and Treasurer at Sarepta Therapeutics.

## SEC filing metadata
- accession: 0001193125-23-004189
- form_type: 8-K
- ticker: SLDB
- cik: 0001707502
- company_name: Solid Biosciences Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1707502/000119312523004189/0001193125-23-004189-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1707502/000119312523004189/d426001d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004189
- JSON: https://secwatch.observer/filing/0001193125-23-004189.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004189.txt

## Key facts
- Executive change
  Kevin Tan was appointed as Chief Financial Officer at Solid Biosciences Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On January 6, 2023, the Company’s Board of Directors (the “Board”) appointed Kevin Tan as the Company’s Chief Financial Officer, effective as of January 9, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1707502/000119312523004189/0001193125-23-004189-index.htm
- Executive change
  Stephen DiPalma departed as Interim Chief Financial Officer at Solid Biosciences Inc..
  - Action: ceased to serve
  - Role: Interim Chief Financial Officer
  source text: In connection with Mr. Tan’s appointment, Stephen DiPalma, the Company’s Interim Chief Financial Officer and principal financial officer and principal accounting officer, will cease to serve in such roles, effective as of the Appointment Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1707502/000119312523004189/0001193125-23-004189-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.